Status:
COMPLETED
A Study of LY3471851 in Participants With Psoriasis
Lead Sponsor:
Nektar Therapeutics
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Psoriasis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may inc...
Eligibility Criteria
Inclusion
- Have a confirmed diagnosis of psoriasis for at least 6 months
- Have active psoriasis plaques according to study- specific criteria
- Be willing and able to undergo skin biopsies
Exclusion
- Have received certain topical medications for psoriasis within 14 days prior to baseline
- Have received certain systemic medications for psoriasis within 4 weeks prior to baseline
- Have received LY3471851 previously
Key Trial Info
Start Date :
November 26 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04119557
Start Date
November 26 2019
End Date
July 21 2021
Last Update
February 20 2024
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States, 72117
2
California Dermatology & Clinical Research Institute
Encinitas, California, United States, 92024
3
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States, 94538
4
Therapeutics Clinical Research
San Diego, California, United States, 92123